This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
October 21 - 23, 2024
Presented in Japan Standard Time

The Westin Miyako Kyoto
Delivered as a Hybrid Event

Ms Vivian Lee
Senior Research Scientist, Protein Therapeutics at Gilead Sciences


Vivian Lee has over 20 years drug development experiences in biotech/pharmaceutical industry including Onyx Pharmaceuticals, Genentech and 23andme. She has established human synthetic antibody phage libraries, a two in one antibody technology, T-cell engager platforms and lead optimization strategies. She currently works as Senior Research Scientist in Protein Therapeutics Department at Gilead Sciences, leading biologics discovery in various therapeutic areas including oncology, inflammation and virology.

Agenda Sessions

  • Unleashing Therapeutic Potential: Bispecific Antibodies Targeting Herpes Simplex Virus Infection for Chronic Suppressive Therapy